Motley Fool Asset Management LLC reduced its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 8.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,035 shares of the biopharmaceutical company’s stock after selling 196 shares during the period. Motley […]
Avitas Wealth Management LLC purchased a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the fourth quarter, Holdings Channel reports. The firm purchased 1,065 shares of the biopharmaceutical company’s stock, valued at approximately $204,000. A number of other institutional investors and hedge funds also recently made changes to their positions […]
Avitas Wealth Management LLC acquired a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 1,065 shares of the biopharmaceutical company’s stock, valued at approximately $204,000. A number of […]
Howland Capital Management LLC acquired a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 4,000 shares of the biopharmaceutical company’s stock, valued at approximately $766,000. Several other hedge funds and other institutional […]
StockNews.com upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) from a hold rating to a buy rating in a report issued on Friday morning. A number of other research firms have also issued reports on ALNY. Morgan Stanley reduced their price target on shares of Alnylam Pharmaceuticals from $184.00 to $176.00 and set an […]